Dr. Lothar Germeroth
(Co-Founder, Investor and Chairman of the Board)
As trained biochemist and serial biotech entrepreneur, Dr. Germeroth is responsible for the strategic planning and commercialization strategy. He holds several patents for automated manufacturing systems and has extensive expertise in founding and developing small and medium Biotechs. Dr. Germeroth was involved in several sucessfull exits and IPO´s (Jerini acquired by Shire; Stage acquired by Juno Therapeutics, Cytos IPO) and is presently member of the management team of Juno Therapeutics and member of the global cell therapy management team after acquisition of Juno by Celgene. He is involved in the development and commercialization of two CAR-T cell products for the treatment of myeloma and lymphoma and is overseeing the entire development and production process until commercialization.
Prof. Dr. Wolfram Zimmermann
(Co-Founder, Scientific Leader and Member of the Board)
Professor for Pharmacology and Director of the Institute of Pharmacology and Toxicology at the University Medical Center Göttingen (UMG) since 2008 and physician/scientist with a longstanding (>20 years) research focus in tissue engineering and tissue engineered heart repair. Prof. Zimmermann and his team have invented several tissue engineering technologies, including the EHM technology. His leadership in the tissue engineering field is documented by having authored more than 150 publications and >10 patents.
Dr. Rainer Knaus (
>20 year experience as Business Unit Manager, Senior Vice President Operations, and Managing Director of various biotech companies. Successfully established manufacturing processes and GMP manufacturing facilities for various cell-based therapeutics in Germany, UK, and US. Supplied first patient-specific Stem-cell and T-cell based cellular therapeutics for commercial use in Germany and the UK.
Dr. Christian Ullrich (Head
>15 years industrial experience in GMP production, GMP quality assurance and quality control with a focus on biopharmaceutical products such as recombinant proteins and advanced therapy medicinal products (ATMPs).
Dr. Malte Tiburcy (Consultant)
Physician/scientist with a board certification in Pharmacology and Toxicology. Group leader at the Institute of Pharmacology and Toxicology at the University Medical Center Göttingen with >10 year experience in tissue engineering. Co-inventor with Prof. Zimmermann on several key technologies licensed by Repairon.